Optimization of pharmacotherapy of patients with prostate adenoma with hormonal and metabolic disordes: correction of vitamin D deficiency with “Aquadetrim”

Authors

DOI:

https://doi.org/10.3897/rrpharmacology.5.49414

Abstract

Introduction: Modern studies demonstrate an epidemiological and pathogenetic role of systemic hormonal and metabolic disorders in men with prostate adenoma (PA), so it is obvious that a pharmacotherapeutic correction of these disorders can increase the efficacy of the traditional therapy of the disease.

Aim of study: To investigate the frequency, relationships among themselves and with PA local parameters of key systemic hormonal and metabolic disorders (obesity, insulin resistance, testosterone deficiency, vitamin D deficiency) and to develop practical algorithms for optimizing diagnosis and management based on an integrative approach.

Material and Methods: The results of a comprehensive examination of 160 patients with PA (main group; average age 62.3 ± 4.2 years) and 30 healthy men without PA of the same age (control group), including: collection of anamnesis and complaints; questionnaires; physical, hormonal and sonographic studies, – are presented. Pharmacotherapeutic correction methods were tested in some patients of the main group. The data was processed using descriptive and comparative statistics.

Results and Discussion: In the patients with PA, a significantly higher frequency of concomitant systemic hormonal and metabolic disorders formed at a younger age was established, compared to the men without PA, and significantly worse local characteristics of PA compared to the patients with PA without such (p < 0.05). Reliable connections of some studied systemic hormonal and metabolic disorders with one another and with local parameters of PA (p < 0.05) were revealed. A more severe vitamin D deficiency in the patients with PA compared to the control group was revealed, and the safety and a significant positive effect of its drug compensation on the parameters of hormonal and metabolic status and PA in D-deficient men with PA were shown (p < 0.05).

Conclusion: The results of the study confirm an important role of the studied systemic hormonal and metabolic disorders in the pathogenesis of PA and the need for their diagnosis and pharmacotherapeutic correction in all patients with PA on the basis of an integrative approach, according to the proposed algorithms.

Keywords:

prostate adenoma, lower urinary tract symptoms (LUTS), nocturia, metabolic syndrome, obesity, insulin resistance, testosterone deficiency, vitamin D deficiency, diagnosis, pharmacotherapy, optimization, integrative approach

Author Contribution

Oleg I. Bratchikov, Kursk State Medical University

Doctor of Medical Sciences, Professor, Head of the Department of Urology.

Igor A. Tyuzikov, Tandem-Plus Medical Center

Doctor of Medical Sciences, Professor, Urologist.

Sergey O. Artishchev, Kursk State Medical University

Postgraduate Student, Department of Urology.

Downloads

Published

30-12-2019

How to Cite

Bratchikov OI, Tyuzikov IA, Artishchev SO (2019) Optimization of pharmacotherapy of patients with prostate adenoma with hormonal and metabolic disordes: correction of vitamin D deficiency with “Aquadetrim”. Research Results in Pharmacology 5(4): 57–67. https://doi.org/10.3897/rrpharmacology.5.49414

Issue

Section

Review article